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As autoimmunity can be the result of a break-
down in peripheral tolerance, determining the 
mechanisms that keep self-reactive T cells in 
check is important for understanding patho-
genesis. Members of the B7/CD28 superfam-
ily of T cell receptors and their cognate ligands 
have been shown to be necessary for the regu-
lation of peripheral T cell function (Keir and 
Sharpe, 2005). This superfamily has members 
that not only provide positive co-stimulatory 
signals that augment and sustain T cell func-
tion but several that contribute critical negative 
signals that down-regulate and inhibit T cell 
responses (Greenwald et al., 2005; Pentcheva-
Hoang et al., 2009). These negative signals are 
especially important in regulating the induction 
of tolerance and autoimmunity. The B7/CD28 
superfamily has been shown to play an impor-
tant role in maintaining tolerance at the feto-
maternal interface (Guleria et al., 2005; Petroff   
and  Perchellet,  2010)  and  also  in  regulating 
autoreactive T cells in disease settings such as 
diabetes (Lühder et al., 1998; Ansari et al., 2003;   
Keir et al., 2006) and experimental autoimmune 
encephalomyelitis (EAE; Perrin et al., 1996; 
Hurwitz et al., 2002; Zhu et al., 2006; Carter 
et al., 2007).
The identification of B7x (B7-H4, B7S1), a 
member of the B7 family, as a negative regula-
tor of T cell activation and function suggested a 
previously unrecognized mechanism by which 
peripheral tolerance can be induced or main-
tained. The initial characterization of B7x dem-
onstrated that its messenger RNA (mRNA) is 
broadly expressed across a wide range of mouse 
organs with its highest expression observed in 
nonhematopoietic tissues (Prasad et al., 2003; Sica 
et al., 2003; Zang et al., 2003). It has since been 
shown that many human cancers exhibit aber-
rant B7x protein expression (Krambeck et al., 
2006; Tringler et al., 2006; Simon et al., 2007; 
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B7x, an inhibitory member of the B7/CD28 superfamily, is highly expressed in a broad 
range of nonhematopoietic organs, suggesting a role in maintaining peripheral tolerance. 
As endogenous B7x protein is expressed in pancreatic islets, we investigated whether the 
molecule inhibits diabetogenic responses. Transfer of disease-inducing BDC2.5 T cells into 
B7x-deficient mice resulted in a more aggressive form of diabetes than in wild-type  
animals. This exacerbation of disease correlated with higher frequencies of islet-infiltrating 
Th1 and Th17 cells. Conversely, local B7x overexpression inhibited the development of 
autoimmunity, as crossing diabetes-susceptible BDC2.5/B6g7 mice to animals overexpressing 
B7x in pancreatic islets abrogated disease induction. This protection was caused by the 
inhibition of IFN- production by CD4 T cells and not to a skewing or expansion of Th2 or 
regulatory T cells. The suppressive function of B7x was also supported by observations from 
another autoimmune model, experimental autoimmune encephalomyelitis, in which  
B7x-deficient mice developed exacerbated disease in comparison with wild-type animals. 
Analysis of central nervous system–infiltrating immune cells revealed that the loss of 
endogenous B7x resulted in expanded Th1 and Th17 responses. Data from these two auto-
immune models provide evidence that B7x expression in the periphery acts as an immune 
checkpoint to prevent tissue-specific autoimmunity.
© 2011 Wei et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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demonstrate that B7x expression protects from self-reactive   
T cell–mediated tissue damage and that this molecule has a 
role in mediating peripheral tolerance.
RESULTS
B7x protein is expressed in the islets of Langerhans
B7x exhibits a unique mRNA expression profile in compari-
son with other members of the B7 family. Canonical mem-
bers such as B7-1 and B7-2 are highly expressed in the 
hematopoietic compartment, predominantly by APCs, and 
rarely, if ever, on nonhematopoietic cells (Hathcock et al., 
1994). In contrast, B7x is most highly expressed in nonlym-
phoid tissues and exhibits an inverse pattern of expression 
when compared with the tissue distribution of B7-2 mRNA 
(Fig. 1 A; Zang et al., 2003). There is very low expression of 
B7x mRNA in the hematopoietic compartment, and we 
did not observe B7x protein expression on murine DCs or 
macrophages even after culturing these cell types in various 
stimulating, suppressive, and maturation conditions (e.g., LPS, 
inflammatory  cytokines, Th1/Th2  cytokines,  and TGF-), 
which differentially regulate the expression of the other 
members of the B7 family (Figs. S1 and S2). However, the 
high levels of B7x mRNA in nonhematopoietic tissues even 
in the absence of maturational or inflammatory stimuli sug-
gest a role for the molecule in inhibiting immune responses 
in the periphery.
As real-time PCR data show relatively high levels of B7x 
mRNA in the pancreas (Fig. 1 A), we examined the tissue for 
B7x protein expression. We harvested pancreata from both 
Zang et al., 2007; Awadallah et al., 2008; Jiang et al., 2010; 
Quandt et al., 2011). Our laboratory has reported that at the 
time of prostatectomy, B7x expression is elevated on prostate 
cancer cells; patients exhibiting the highest levels of the mole-
cule on their tumors had increased risk of recurrence, spread 
of disease, and mortality (Zang et al., 2007). This correlation 
of increased B7x expression with poor prognosis has also been 
observed in other human cancers, suggesting that expression 
of this inhibitory molecule might facilitate tumor progression 
by inhibiting host immunity (Jiang et al., 2010; Quandt et al., 
2011). In this study, we sought to determine whether tissue-
specific B7x expression can suppress self-reactive host immune 
responses and protect from autoimmunity in two disease 
models: diabetes and EAE.
As B7x protein can be detected on the islets of Langer-
hans, we examined whether the molecule has a role in main-
taining tolerance against diabetogenic T cells. In an adoptive 
transfer model of diabetes, the injection of activated diabeto-
genic T cells into B7x-deficient animals resulted in a more 
severe disease than in wild-type control mice. As the loss of 
B7x exacerbated disease, we also studied whether the over-
expression of B7x could delay or prevent the aggressive form 
of diabetes that develops in BDC2.5/B6g7 animals. Pancreatic 
overexpression of B7x in BDC2.5/B6g7 mice abrogated disease 
induction and inhibited cytokine production by the patho-
genic T cells. Examining the role of B7x in another model of 
autoimmunity supports the suppressive in vivo effect of B7x, 
as EAE induced in B7x-deficient mice is more severe rela-
tive to disease in wild-type mice. Therefore, our experiments 
Figure 1.  B7x is highly expressed in the pancreas, specifically in the islets of Langerhans. (A) Real-time PCR on cDNA isolated from the organs 
of C57BL/6 mice with B7x or B7-2 primers. Expression data were normalized relative to HPRT. Data are representative of three independent experiments. 
Error bars represent the SD among the different mouse samples. (B) Pancreatic sections from B7x-deficient and B7x wild-type mice were stained for  
B7x (red), insulin (green), and DAPI (blue). Bars, 10 µm.JEM Vol. 208, No. 8 
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As several studies have concluded that Th1 cells, or CD4 
T cells characterized by IFN- production, promote disease 
(Healey et al., 1995; Katz et al., 1995; Liblau et al., 1995), in 
a diabetogenic setting, we examined the infiltrating cells 
for cytokine production. A higher percentage of pancreas- 
infiltrating  BDC2.5 T  cells  in  B7x-deficient  animals  pro-
duced IFN- upon in vitro restimulation in comparison with 
the wild-type controls (Fig. 3, B and D). Although it is not yet 
known whether this decrease in cytokine production in the 
wild-type  mice  is  caused  by  a  direct  interaction  between 
B7x-expressing islets and IFN-–producing CD4 T cells, this 
result correlated with previous in vitro data demonstrating 
B7x-mediated inhibition of IFN- production by CD4 T cells 
(Zang et al., 2003).
Several groups have demonstrated that IL-17 seems to 
promote  disease  progression  in  certain  models  of  diabetes 
(Miljkovic et al., 2005; Mensah-Brown et al., 2006; Jain et al., 
2008); however, others have questioned the requirement of 
Th17 cells in the development of disease (Bending et al., 2009; 
Martin-Orozco et al., 2009). As the role of Th17 cells has not 
been clearly defined in this adoptive transfer model of diabe-
tes, we examined IL-17 production in the pancreata of the 
wild-type  and  B7x-deficient  mice  for  immunofluorescent 
staining. Histological staining of the pancreatic sections dem-
onstrated that B7x colocalizes with insulin, indicating that 
B7x is specifically expressed in the islets of Langerhans 
(Fig. 1 B). It has already been shown that pancreatic expres-
sion of PD-L1, another inhibitory member of the B7 family, 
plays an important role in preventing diabetes by suppressing 
islet-reactive T cells (Ansari et al., 2003). Therefore, to deter-
mine whether B7x can also inhibit diabetogenic responses, 
we examined whether the loss of B7x could exacerbate dis-
ease in an adoptive transfer model of diabetes.
Loss of B7x results in exacerbated disease after adoptive 
transfer of diabetogenic T cells
To establish a highly aggressive and synchronized form of dia-
betes, we used BDC2.5 transgenic (tg) mice; these mice carry 
rearranged TCR  and  chain genes from a nonobese dia-
betic (NOD)–derived CD4 T cell clone (Katz et al., 1993). 
Transfer of activated BDC2.5 splenocytes into neonatal NOD, 
NOD.scid, or sublethally irradiated NOD and B6g7 recipients 
results in a rapid induction of diabetes with reproducible 
kinetics and incidence (Katz et al., 1995; Pakala et al., 1999; 
Calderon et al., 2006). We find that the adoptive transfer of   
10 × 106 Con A–activated BDC2.5/B6g7 splenocytes into 
sublethally irradiated B6g7 mice results in diabetes in 100% of 
mice within 40 d after transfer (unpublished data). Therefore, 
in our experiments, we transferred 10 × 106 Con A–activated 
BDC2.5/B6g7 splenocytes into sublethally irradiated B7x- 
deficient and wild-type mice and compared disease progression. 
Diabetes induced in B7x-deficient mice is more aggressive 
than in wild-type control mice as shown by earlier onset   
of disease (Fig. 2 A), higher mean glucose measurements 
(Fig. 2 B), and earlier lethality of disease in the B7x knockout 
recipients (Fig. 2 C).
IFN- and IL-17 expression by islet-infiltrating CD4  
T cells is significantly increased in the pancreata  
of B7x-deficient mice
To determine the mechanisms by which the loss of B7x is 
exacerbating disease, we harvested the pancreata of the recipi-
ents 5 d after transfer and analyzed the infiltrating cells. 
B7x-deficient recipients had statistically greater numbers of 
congenically marked CD4 T cells in the pancreas relative to 
their wild-type controls (Fig. 3 A). An important factor in de-
termining diabetes progression is the ratio of suppressive reg-
ulatory T cells (Treg cells) to pathogenic effector T cells (T eff cells; 
Herman et al., 2004; Tang et al., 2004; Tarbell et al., 2004, 
2007). To assess the role of Treg cells in this disease setting, we 
examined pancreatic infiltrating CD4 T cells for FoxP3 ex-
pression. Pancreatic B7x expression could be mediating a pro-
tective effect by expanding a Treg cell population. However, in 
this model, we observed a similar low frequency of FoxP3+ 
cells in the pancreata of both recipient groups (Fig. 3 E). Thus, 
the exacerbation of disease in B7x-deficient animals cannot 
be attributed to a lower frequency of suppressive Treg cells in 
the pancreatic environment.
Figure 2.  Loss of B7x results in exacerbated disease after adoptive 
transfer of diabetogenic T cells. (A–C) After transfer of activated 
BDC2.5 cells into sublethally irradiated recipient mice, urine glucose levels 
were measured every 2 d. Mice were considered diabetic after two con-
secutive measurements exceeded 250 mg/dl. B7x-deficient mice (blue) 
exhibited a more severe disease in comparison with wild-type mice (black) 
when we examined disease incidence (A), mean glucose measurements (B), 
and survival (C; n = 15 mice per group). Data were pooled from three 
independent experiments.1686 B7x protects from T cell–mediated autoimmunity | Wei et al.
neutralizing IL-17A 
antibody developed 
disease at the same 
rate  as  the  recipi-
ents that received 
an  isotype  control   
(Fig. S3 B). These results indicate that although IL-17 may 
contribute to diabetogenic responses, it is not required for 
disease induction, whereas IFN- is necessary for the patho-
genic responses of BDC2.5 T cells.
B7x mRNA and protein are overexpressed in pancreatic 
islets of RipB7x tg mice
Recent papers have reported that the ectopic overexpression 
of B7x results in prolonged graft survival in an allogeneic islet 
transplantation  model;  however,  the  mechanism  by  which 
B7x mediates this effect remains unclear (Wang et al., 2009; 
Yuan et al., 2009). Therefore, we sought to determine whether 
the overexpression of B7x can suppress the development of 
an aggressive form of diabetes.
To overexpress B7x in pancreatic islets, we used 
a construct that drives B7x expression under the 
rat insulin II promoter to generate the RipB7x tg 
mouse. As this promoter has been shown to be 
slightly promiscuous, B7x is expressed at low levels 
in pancreatic LNs (PLNs) and spleens; however, 
the largest increase in B7x mRNA levels was in 
the pancreas, where we observed 200-fold higher 
B7x  expression  (Fig.  4  A).  The  elevated  B7x 
mRNA levels correspond to increased B7x pro-
tein when comparing immunofluorescent staining 
of B7x in pancreata from RipB7x tg mice and 
B7x-deficient and wild-type mice. We found that a large per-
centage of the BDC2.5 T cells in the pancreata of both groups 
of  animals  produced IL-17.  However,  a  statistically higher 
percentage of the pancreatic T cells from the B7x knockout 
group produced the cytokine in comparison with the wild-
type animals (Fig. 3, B and C). These data suggest that pancre-
atic expression of B7x can decrease IL-17 levels in vivo.
Although we have demonstrated that endogenous levels 
of B7x in pancreatic islets can inhibit cytokine production by 
diabetogenic T cells, the requirement for IFN- and IL-17 in 
mediating disease in this adoptive transfer model is unknown. 
To determine the roles of these inflammatory cytokines,   
we administered neutralizing antibodies to either IFN- or   
IL-17  after  transfer  of  activated  BDC2.5  splenocytes  into 
B6g7 recipients. Blockade of IFN- resulted in a complete 
abrogation of disease, which is consistent with published re-
ports on the importance of this cytokine in promoting dia-
betes (Fig. S3 A; Healey et al., 1995; Katz et al., 1995; Liblau 
et al., 1995). However, recipients that were treated with 
Figure 3.  Loss of B7x results in increased 
numbers of transferred diabetogenic  
T cells and enhanced production of IFN- 
and IL-17 in the pancreata. 5 d after trans-
fer of activated BDC2.5 splenocytes, the pan-
creata were harvested. (A) Absolute number of 
transferred CD4+ T cells normalized to pancre-
atic weight. (B) Representative FACS plots 
showing cytokine production by transferred 
CD4+CD45.1+ cells in pancreatic islets of B7x-
deficient (right) and wild-type (left) recipients. 
(C) Percentage of transferred CD4+CD45.1+  
T cells that express IL-17 in the pancreata.  
(D) Percentage of transferred CD4+CD45.1+  
T cells that express IFN- in the pancreata.  
(E) Percentage of transferred CD4+CD45.1+  
T cells that are FoxP3 positive in the pancreata. 
Three independent experiments were pooled. 
Error bars represent the SEM, and black hori-
zontal bars indicate the mean. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001.
Figure 4.  RipB7x transgenic mice show increased 
expression of B7x in pancreatic islets. (A) Real-time 
PCR data of B7x expression in the pancreata of tg (red) and 
wild-type (blue) mice. Data are representative of three 
independent experiments. Black horizontal lines indicate 
the mean. (B) Immunofluorescent staining of pancreatic 
sections from wild-type (top) and RipB7x tg (bottom) mice 
for B7x, insulin, and DAPI (blue). Bars, 10 µm.JEM Vol. 208, No. 8 
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mice showed hyperaggressive insulitis in both BDC2.5+ 
RipB7x and BDC2.5+RipB7x+ mice (Fig. 5 A), demon-
strating that overexpression of B7x on pancreatic islets does 
not prevent insulitis.
Despite the aggressive insulitis observed in both groups of 
mice, by 10 wk of age, 80% of BDC2.5+RipB7x mice 
had become diabetic, whereas the BDC2.5+RipB7x+ group 
(0/11) remained free of disease (Fig. 5 B). As previously pub-
lished, BDC2.5 mice that are not diabetic by 10 wk of age do 
not develop the disease later (Gonzalez et al., 1997). There-
fore, the data suggest that although the overexpression of B7x 
in pancreatic islets does not prevent insulitis, it results in com-
plete abrogation of clinical disease.
IFN- and IL-17 expression by islet-infiltrating BDC2.5  
T cells is markedly reduced in RipB7x+ mice
To determine the mechanism by which B7x overexpression 
exerts its protective effect, we characterized the infiltrating 
cells from the pancreata of BDC2.5+RipB7x+ and BDC2.5+ 
RipB7x mice at 1 mo of age. Although there was no differ-
ence in the number of BDC2.5 T cells (CD4+V4+ cells) in 
the pancreata (Fig. 6 A), there was decreased cytokine produc-
tion by the T cells in RipB7x+ mice. Intracellular cytokine 
staining for IFN- showed that a significantly lower percent-
age of CD4+V4+ T cells from the pancreata of BDC2.5+ 
RipB7x+ animals produced the cytokine upon in 
vitro restimulation in comparison with CD4+V4+ 
T cells from BDC2.5+RipB7x mice (Fig. 6, B 
and D). This decrease in IFN-–producing BDC2.5 
T cells can also be observed in the PLNs and spleens 
of BDC2.5+RipB7x+ mice (Fig. 6 D). We also ex-
amined IL-17 production in the pancreata of the 
BDC2.5+RipB7x+  and  BDC2.5+RipB7x  mice. 
BDC2.5+RipB7x mice have a significantly greater 
percentage of IL-17–producing CD4+V4+ cells 
in the pancreata, PLNs, and spleens than BDC2.5+ 
RipB7x+ mice (Fig. 6, C and E). These results sug-
gest that the overexpression of B7x is inhibiting 
IFN- and IL-17 cytokine production by diabeto-
genic T cells, resulting in an amelioration of disease.
A potential mechanism for B7x-mediated inhibi-
tion of diabetes could be the preferential inhibition 
of Th1 cells, allowing for the expansion of Th2 cells. 
The balance between the two subsets in a diabetes 
setting is important as several studies have concluded 
that Th1 cells, characterized by IFN- production, 
from wild-type C57BL/6 mice (Fig. 4 B). As B7x staining in 
RipB7x pancreatic sections colocalizes with islet insulin stain-
ing, it seems that the molecule is overexpressed in the correct 
cell type to inhibit diabetogenic T cells.
Overexpression of B7x in the pancreatic islets of BDC2.5 
mice does not prevent insulitis but abrogates progression  
to disease
We crossed RipB7x tg mice that had been bred onto the B6g7 
background to BDC2.5 tg mice. Backcrossing the BDC2.5 tg 
onto  a  B6g7  (C57BL/6  strain  with  the  NOD  haplotype) 
background results in an aggressive onset of diabetes, with 
>60% of mice exhibiting disease at 10 wk of age (Gonzalez   
et al., 1997). It was hypothesized that overexpression of B7x 
could modulate the aggressive and highly penetrant form of 
the disease in BDC2.5/B6g7 animals. We first compared the 
development  of  insulitis  in  BDC2.5/B6g7  mice  that  were 
positive  for  the  RipB7x  transgene  (BDC2.5+RipB7x+)  to 
BDC2.5/B6g7 mice that were negative for the RipB7x trans-
gene (BDC2.5+RipB7x). Starting around day 18, BDC2.5/
B6g7 mice developed a highly aggressive form of insulitis 
characterized by severe inflammation marked by edema around 
the  islets  and  large  numbers  of  infiltrating  lymphocytes 
and inflammatory cells (Gonzalez et al., 1997). Hematoxylin- 
and eosin (H&E)-stained pancreatic sections from 32-d-old 
Figure 5.  Overexpression of B7x in the pancreata of 
BDC2.5 mice does not prevent insulitis but does abrogate 
induction of disease. (A) Representative H&E staining of pan-
creatic sections from 32-d-old mice. The pancreata were iso-
lated from BDC2.5+RipB7x mice (left), BDC2.5+RipB7x+ mice 
(middle), and B6g7 control mice (right). Bars, 50 µm. (B) Disease 
incidence in BDC2.5+RipB7x (blue; n = 17), BDC2.5+RipB7x+ 
(red; n = 11), and B6g7 (black; n = 9) mice for over 10 wk. Data 
were pooled from four independent experiments.1688 B7x protects from T cell–mediated autoimmunity | Wei et al.
disease state in BDC2.5/NOD mice. It has been shown that 
blockade of ICOS, a B7 co-stimulatory molecule which is 
highly expressed on pancreatic Treg cells, changes the gene ex-
pression profiles of infiltrating Treg cells toward a less suppres-
sive phenotype (Herman et al., 2004). This results in a skewing 
of the T eff/Treg cell ratio toward T eff cells, which manifests in 
the conversion of benign insulitis to diabetes. The T eff/Treg cell 
ratio was not markedly different between the pancreata of 
BDC2.5+RipB7x and BDC2.5+RipB7x+ animals (Fig. S4 E). 
Therefore, overexpression of B7x does not protect from dis-
ease induction by expanding the Treg cell population.
Genetic ablation of B7x exacerbates myelin oligodendrocyte 
glycoprotein (MOG)–induced EAE disease
As the results from our two models of diabetes showed that 
modulation of pancreatic B7x expression can determine dis-
ease susceptibility, we investigated whether the molecule has 
a more general role in protecting peripheral tissues from   
immune-mediated destruction by examining its function in 
EAE. EAE is a CD4 T cell–mediated autoimmune attack of 
the myelin sheath in the central nervous system (CNS) and 
serves as an animal model for multiple sclerosis (Ben-Nun 
et al., 1981; Ando et al., 1989). The first stage of disease is 
characterized by a perivascular infiltration of the CNS by 
myelin-reactive CD4 T cells. This is followed by an influx of 
mononuclear cells such as activated macrophages that strip 
the myelin from axons (Renno et al., 1995). The resulting   
demyelination of the CNS clinically manifests as progressive 
paralysis. To address whether endogenous B7x expression has 
a role in inhibiting myelin-reactive T cells in the CNS, we in-
duced EAE in B7x-deficient and wild-type mice and exam-
ined disease incidence.
We induced suboptimal disease to reveal any inhibitory 
effects mediated by endogenous B7x. After titrating vary-
ing amounts of MOG peptide, we established a protocol 
that induces low-grade EAE. EAE induced on the 129/SvE 
background showed a reproducible exacerbation of disease 
in the B7x-deficient mice in comparison with their wild-
type counterparts, as animals from the B7x-deficient group 
exhibited higher mean clinical scores than wild-type co-
horts (Fig. 7).
promote disease (Healey et al., 1995; Katz et al., 1995; Liblau 
et al., 1995), whereas Th2 cells, characterized by IL-4 produc-
tion, either protect from diabetes or promote a clinically silent 
peri-insulitis (Healey et al., 1995; Katz et al., 1995; Mueller   
et al., 1996, 1997). Thus, we assessed the role of Th2 cells in 
our system by examining IL-4 production in the pancreata of 
our mice. We found that IL-4 levels in the pancreata of both 
BDC2.5+RipB7x+ and BDC2.5+RipB7x mice were very 
low (Fig. S4, A and B) and that there was no difference in the 
percentage of IL-4–producing cells between the two groups 
of mice. Therefore, it seems that the overexpression of B7x 
does not mediate its protective effect through the expansion 
of a Th2 population.
Another possible mechanism by which B7x overexpres-
sion in the pancreata of BDC2.5+RipB7x+ mice could be 
mediating its protective effect is by expanding a Treg cell 
population and thereby preventing disease induction. How-
ever,  we  found  that  mice  from  the  diabetes-susceptible 
BDC2.5+RipB7x group had higher percentages of Treg cells 
than their RipB7x+ counterparts (Fig. S4, C and D), most 
likely reflecting the more destructive state of inflammation in 
the pancreata of BDC2.5+RipB7x animals. The balance 
between Teff and Treg cells is also important is determining 
Figure 6.  Overexpression of B7x in the pancreata results in inhibi-
tion of IFN- and IL-17 production by BDC2.5 T cells. (A) Absolute 
number of CD4+V4+ T cells normalized to pancreatic weight.  
(B and C) Representative dot plots of intracellular IFN- (B) and IL-17 (C) 
staining of the pancreata from BDC2.5+RipB7x (left) and BDC2.5+RipB7x+ 
(right) animals. Populations were gated on pancreatic CD4+ T cells.  
(D and E) Percentage of CD4+V4+ T cells that produced IFN- (D) or IL-17 
(E) in each organ. BDC2.5+RipB7x are shown in blue; BDC2.5+RipB7x+ are 
shown in red. Data are representative of three independent experiments. 
Black horizontal lines indicate the mean. *, P < 0.05; **, P < 0.01.
Figure 7.  Induction of EAE in B7x knockout mice results in exac-
erbated disease on the 129/SvE background. After induction of disease, 
mice were observed for 2 mo for clinical signs of EAE. Data are the mean 
clinical score and are representative of three independent experiments  
(n = 8–10 mice per group). P < 0.0001.JEM Vol. 208, No. 8 
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expression could be promoting the greater severity of disease 
in the knockout mice.
There is not a significant difference between the frequency 
of Treg cells in the CNS of B7x/ 129/SvE mice and  
wild-type control mice
To determine whether B7x deficiency was affecting the fre-
quency of Treg cells in the CNS of B7x/ 129/SvE animals, 
we examined FoxP3 expression in the infiltrating CD4 T cells. 
The percentage of CD4 T cells that were FoxP3 positive did 
not differ between the two groups (Fig. 9 A). Although there 
was an increased number of Treg cells in the CNS of B7x- 
deficient animals because of the increased numbers of total CD4 
T cells in these mice, analysis of the T eff/Treg cell ratios showed 
that that the increase in T eff cells is greater than the increase in 
Treg cells in the B7x knockout mice (Fig. 9 B). Thus, these data 
indicate that B7x does not play a role in modulating the fre-
quency of Treg cells in the autoimmune model of EAE.
DISCUSSION
Although  high  expression  of  most  B7  family  members  is 
largely restricted to immune cells, especially APCs, we were 
not able to detect protein expression of B7x in any cell type 
of  hematopoietic  origin. This  strongly  suggested  that  B7x 
does not play a role in regulating T cell priming in the lym-
phoid  organs.  However,  histological  staining  of  pancreatic 
sections demonstrated constitutive expression of B7x in the 
islets of Langerhans, indicating that this inhibitory molecule 
may have a role in maintaining peripheral tolerance to islet-
reactive T cells. It has already been shown that PD-L1,   
another member of the B7 family, plays an important role in 
preventing diabetes by inhibiting islet-reactive T cells (Ansari 
et al., 2003). Although PD-L1 has been reported to be ex-
pressed at very low levels (Liang et al., 2003) or absent (Ansari 
et al., 2003) in naive pancreata, its expression is up-regulated 
in an age-dependent manner in NOD mice. Using bone 
marrow chimeras, it was shown that PD-L1 expression on 
parenchymal rather than hematopoietic cells protects against 
disease in NOD mice (Keir et al., 2006). Furthermore, PD-L1 
expression on islets results in protection from autoreactive   
Characterization of CNS cellular infiltrate in B7x/ 129/SvE  
mice reveals significant increases in the absolute numbers 
of activated CD4 T cells and Th1 and Th17 cells
As Th1 and Th17 subsets of CD4 T cells are determining fac-
tors in EAE induction, we characterized the cellular infiltrates 
in the CNS of B7x/ 129/SvE and wild-type animals at   
day 14 after disease induction. Absolute numbers of activated 
CD4 T cells (CD4+CD44hi) infiltrating the brain and spinal 
cord were significantly higher in B7x/ 129/SvE animals 
than in wild-type controls (Fig. 8 A). As expected, the abso-
lute numbers of activated CD4 T cells in the CNS of the 
immunized mice were also significantly higher than the un-
immunized wild-type controls, reflecting the diseased state of 
the MOG-immunized mice (Fig. 8 A).
Analysis of Th1 and Th17 populations from the CNS cel-
lular infiltrates revealed a significantly higher frequency of 
both IFN-– and IL-17–producing CD4 T cells in the B7x/ 
129/SvE animals in comparison with wild-type controls (Fig. 8, 
B and C, left). The absolute number of pathogenic Th1 and 
Th17 cells in the CNS of these mice also showed highly 
significant differences between the B7x-deficient and wild-
type animals (Fig. 8, B and C, right). These results indicate that 
B7x deficiency promotes the expansion of Th1 and Th17 
cells during EAE induction and that this increase of cytokine 
Figure 8.  Flow cytometric analysis of cellular infiltrate in the CNS 
of B7x/ 129/SvE mice 14 d after induction of EAE. On day 14 after 
antigen immunization, mononuclear cells from the CNS were isolated and 
restimulated with PMA/ionomycin for intracellular cytokine staining.  
(A) Absolute numbers of activated CD4 T cells (CD4+CD44hi). (B) Percentage 
of CD4+ T cells producing IFN- (left) and absolute numbers of Th1 cells 
(right). (C) Percentage of CD4+ T cells producing IL-17 (left) and absolute 
numbers of Th17 cells. B7x-deficient mice are shown in blue; wild-type 
mice are shown in red; unimmunized control mice are shown in black. Data 
were pooled from three independent experiments. Black horizontal lines 
indicate the mean. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 9.  No significant difference in the percentages of Treg cells 
in the CNS of B7x/ 129/SvE mice and wild-type controls at day 14 
after induction of disease. (A) Percentage of CD4+ T cells that are  
FoxP3 positive in the CNS. (B) Ratio of Teff/Treg cells. B7x-deficient mice are 
shown in blue; wild-type mice are shown in red; unimmunized control 
mice are shown in black. Data were pooled from three independent ex-
periments. Black horizontal lines indicate the mean. **, P < 0.01.1690 B7x protects from T cell–mediated autoimmunity | Wei et al.
(Mensah-Brown et al., 2006). More direct evidence for the 
role of IL-17 in the induction of diabetes was demonstrated 
when polarized Th17 cells were shown to induce diabetes in 
NOD.scid recipients; this disease was abrogated upon admin-
istration of neutralizing antibody to IL-17A (Jain et al., 2008). 
Thus, the presence of IL-17 seems to promote disease pro-
gression. The inhibition of IL-17 production that we observed 
in the pancreata of BDC2.5+RipB7x+ protected mice could 
be contributing to the abrogation of diabetes.
However, several recent studies questioned the require-
ment of Th17 cells in the induction of diabetes. Although 
disease can be induced in NOD.scid mice by the transfer of 
polarized BDC2.5 Th17 cells, diabetes onset was concomitant 
with the conversion of pancreatic infiltrates from a Th17 to a 
Th1 phenotype (Bending et al., 2009; Martin-Orozco et al., 
2009). Thus, although diabetogenic Th17 cells appear to be 
pathogenic, these studies demonstrate that it is the conversion 
to a Th1 phenotype that allows for disease development.   
Another study has shown that transfer of polarized Th17 cells 
from CFA-immunized NOD mice can delay the develop-
ment of disease in a transfer model of diabetes, suggesting a 
protective role for IL-17–producing cells (Nikoopour et al., 
2010). Our own experiments neutralizing IL-17 in an adop-
tive transfer model of diabetes support reports that the cyto-
kine is not necessary for mediating disease (Bending et al., 2009; 
Martin-Orozco et al., 2009). However, this conclusion does 
not preclude a role for IL-17 in shaping a diabetogenic response; 
further study is needed to determine how the cytokine could 
be modulating tissue inflammation during disease.
We also examined another model of autoimmunity to de-
termine whether B7x has a more general role in protecting 
tissues from damage by self-reactive T cells. As data from our 
two models of diabetes demonstrated an inhibitory role for 
B7x on CD4 T cells, we investigated another model of auto-
immunity initiated by Th1 and Th17 cells. The induction of 
EAE in B7x-deficient mice reveals that the loss of this sup-
pressive molecule results in an exacerbation of disease, demon-
strating that the B7x pathway can also regulate MOG-reactive 
T cell responses.
Another  study  has  shown  that  administration  of  B7x 
blocking antibody exacerbates disease in an EAE model; 
however, it did not investigate the cellular mechanisms of this 
result (Prasad et al., 2003). We examined the populations of 
CNS-infiltrating CD4 T cells to dissect out the differences 
between the B7x-deficient and wild-type mice. Aggravation 
of disease correlates with increased numbers of activated CD4 
T cells and Th1 and Th17 cells in the CNS of B7x/ 129/
SvE mice. It seems that the loss of the inhibitory B7x mole-
cule during EAE induction promotes both Th1 and Th17   
expansion in the CNS without affecting the frequency of 
the Treg cell population. Initially, Th1 cells were thought to be 
the mediators of EAE by promoting tissue inflammation.   
The predominant production of IFN- in the spleen and 
CNS during EAE supported the theory that Th1 cells were 
the pathogenic T cell subset responsible for disease (Merrill   
et al., 1992). Moreover, the recovery phase of disease correlated 
T cells in diabetic mice in an islet transplantation model. There-
fore, to determine whether the B7x pathway also plays a role 
in inhibiting diabetogenic responses, we examined whether 
the modulation of B7x expression in the pancreas could affect 
disease incidence.
In an adoptive transfer model of diabetes, we observed 
that B7x-deficient mice exhibited more aggressive disease than 
wild-type mice. Analysis of the infiltrating BDC2.5 T cells re-
vealed that the loss of endogenous B7x resulted in increased 
numbers of Th1 and Th17 cells in the pancreata. This exacer-
bation of disease cannot be attributed to changes in Treg cell 
frequencies and correlates with increased production of IFN- 
and IL-17 by the activated BDC2.5 T cells. As the loss of 
B7x expression resulted in more severe diabetes, we also ex-
amined whether the overexpression of the molecule could 
prevent disease. We found that the overexpression of B7x in 
the pancreata of BDC2.5 mice resulted in complete abroga-
tion of diabetes. To determine how B7x exerts its amelio-
rating effect, we examined Th1, Th2, Th17, and Treg cell 
populations in the pancreata, PLNs, and spleens of BDC2.5+ 
RipB7x+ and BDC2.5+RipB7x mice. We demonstrated 
that the protective effect of B7x overexpression was not   
mediated by either an expansion of or skewing toward a Th2 
or Treg cell population. In contrast, we observed that there was 
a significant inhibition of IFN- and IL-17 production by 
CD4 T cells in the pancreata of the B7x-overexpressing mice. 
Therefore, in both models of diabetes, we find that the 
presence of B7x results in an inhibition of inflammatory 
cytokine production.
The importance of IFN- in autoimmune diabetes has 
been shown by the marked inhibition of both insulitis and 
disease in NOD mice lacking the IFN- receptor  chain. 
BDC2.5 transgenics with the same null mutation in the IFN- 
receptor  chain also display a complete abrogation of disease 
(Wang et al., 1997). This lack of disease induction has been 
attributed to the loss of IFN-R on  cells and APCs such as 
macrophages. It has been postulated that the loss of IFN-  
responsiveness inhibits the up-regulation of MHC class I and II 
molecules and also prevents efficient killing of  cells as this 
cytokine has been shown to regulate apoptosis and iNOS (in-
ducible nitric oxide synthetase) production. Recently, it was 
reported  that  activated  macrophages  are  key  mediators  of   
 cell death in an adoptive transfer model of diabetes using 
activated BDC2.5 T cells (Calderon et al., 2006). As IFN- is 
known to be a potent activator of macrophage function,   
inhibition of this cytokine by pancreatic B7x could be pre-
venting proper antigen presentation and the efficient killing 
of  cells by macrophages.
Several studies have recently begun to address the role of 
IL-17 and Th17 cells in diabetes. It has been shown that IL-17 
augments IFN-–, TNF-, and IL-1–induced iNOS mRNA 
and protein expression in an insulinoma cell line (MIN6) and 
also in pancreatic islet cells (Miljkovic et al., 2005). Another 
study has shown that IL-23, which promotes the develop-
ment of Th17 cells, can enhance disease induction in a model 
of subdiabetogenic treatment with low doses of streptozotocin JEM Vol. 208, No. 8 
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and stained with the following antibodies: B7x (clone 9; eBioscience), V4 
(clone KT4; BD), CD4 (clone RM4-5; eBioscience), CD4 (clone L3T4; 
eBioscience), IAg7 (clone 10.2.16; MSKCC Monoclonal Antibody Core), 
IAb  (clone Y3P;  MSKCC  Monoclonal Antibody  Core),  IgG1  (clone 
eBRG1;  eBioscience),  CD11.c  (clone  N418;  eBioscience),  F4/80  (clone 
BM8; eBioscience), and FoxP3 (clone FJK-16s; eBioscience), Intracellular 
cytokine staining was performed after restimulation with 50 ng/ml PMA and 
1 µg/ml ionomycin for 5 h in the presence of monensin (eBioscience). 
The cells were fixed and permeabilized using Cytofix/Cytoperm (BD) ac-
cording to the manufacturer’s instructions. The cells were stained with anti–
IFN-  (XMG1.2;  eBioscience),  anti–IL-4  (11B11;  BD),  or  anti–IL-17 
(TC11-18H10; BD). The samples were analyzed with a CyAn (Dako) or 
LSRII (BD) flow cytometer. Flow cytometry data were analyzed with FlowJo 
(Tree Star).
The hybridoma producing neutralizing antibody to IL-17A was a gift 
from J. van Snick (Ludwig Institute for Cancer Research, Brussels, Belgium). 
Anti–IFN- (XMG1.2), rat IgG1 isotype control (HRPN), and mouse IgG1 
isotype control (MOPC-21) were obtained from BioXcell.
RNA preparation and real-time PCR. RNA was isolated from homog-
enized tissue or harvested cell lines using TRI Reagent (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. The RNA samples were reverse 
transcribed using Ready-To-Go You-Prime First-Strand Beads (GE Health-
care). Quantitative PCR was performed on a real-time PCR system (model 
7500; Applied Biosystems). Premade TaqMan primer/probe gene expression 
assays for each gene analyzed were purchased from Applied Biosystems (B7x, 
Mm00628552_m1; B7-2, Mm00444543_m1; and HRPT, Mm00446968_A1). 
HPRT was used as the endogenous control, and relative changes in gene ex-
pression were calculated using the Ct method.
Isolation and activation of DCs. Bone marrow from the femur and tibia 
was isolated and cultured with 10 ng/ml GM-CSF for 6 d and then matured 
for 48 h with 2.5 ng/ml TNF, 2.5 ng/ml TNF + 10 ng/ml IL-10, 1 µg/ml 
LPS, LPS + TNF, or LPS + TNF + IL-10. All cytokines were purchased from 
R&D systems.
Isolation and activation of macrophages. To induce inflammatory macro-
phages, mice were injected with 3–4 ml of 4% thioglycolate (BD). 72 h 
later, peritoneal macrophages were washed out with RPMI 1640 medium. 
The exudate was then adhered onto 12-well plates for 12 h. Unless otherwise 
stated, the macrophages were then cultured with medium alone or activated 
with 20 ng/ml IL-4, 100 ng/ml IFN- + LPS, 500 ng/ml IL-6 + 50 ng/ml 
IL-10, or 5 ng/ml TGF-. All cytokines were purchased from R&D systems. 
Treg cells were isolated using a Miltenyi Biotec isolation kit. Macrophages 
were cultured in media alone with Treg cells (CD4+CD25+ cells) or with 
CD4+CD25 cells in the presence of 10 µg/ml soluble anti-CD3 and 5 µg/ml 
anti-CD28. The mixed cultures were set up at a 1:2 ratio with 0.5 × 106 
macrophages and 1.0 × 106 T cells. After treatment, the macrophages were 
harvested with a cell scraper for FACS analysis.
Monitoring for diabetes. Starting from 3 wk of age, urine glucose levels 
of mice were measured with Diastix (Bayer) testing strips. Mice were consid-
ered diabetic after two consecutive measurements exceeding 250 mg/dl. The 
first positive measurement was defined as the onset of diabetes.
Isolation of pancreatic islet cells. Mice were sacrificed, and the pancreata 
were resected. After mincing into small pieces, the pancreata were digested 
with Collagenase P (Roche) by vigorous shaking in a water bath at 37°C. 
The digested islets were hand-picked using a dissection microscope (SZ30; 
Olympus) and dispersed by pulling through an 18-gauge needle. The single 
cell suspensions were then analyzed by flow cytometry.
Adoptive  transfer  of  activated  BDC2.5  splenocytes.  Spleens  were   
harvested from BDC2.5/B6g7 transgenic mice and activated with 5 µg/ml 
Con A (Sigma-Aldrich). After 3 d of culture, cells were washed with 0.2 M 
methyl--d-mannopyranoside  (Sigma-Aldrich). The  activated  BDC2.5/B6g7 
with a decrease in IFN- production in the CNS (Kennedy 
et al., 1992; Khoury et al., 1992). These data strongly sug-
gested that the myelin-specific T cells mediating disease were 
Th1 T cells secreting the disease-promoting cytokine IFN-.
However, more recent publications have shown that in 
mice, autoreactive IL-17–producing CD4 T cells are the domi-
nant pathogenic T cells in EAE (Langrish et al., 2005; Komiyama 
et al., 2006). Although IL-17 may be the effector cytokine 
that mediates tissue damage and induces immunopathology 
in EAE, there is still a role for IFN-–producing Th1 cells in 
the induction of disease. Using an adoptive transfer model of 
EAE, it was recently shown that although polarized Th1 cells 
were capable of inducing disease, a Th17 culture lacking Th1 
cells was unable to initiate EAE (O’Connor et al., 2008). This 
inability of the Th17 cells to induce disease was attributed to 
the observation that only Th1 cells could access noninflamed 
CNS. It was speculated that the establishment of inflamma-
tory lesions in the CNS by Th1 cells is what allows for the 
eventual recruitment of pathological Th17 cells. Therefore, 
the expansion of both Th1 and Th17 cells in the CNS of 
B7x-deficient mice is most likely the cause of exacerbated 
disease after EAE induction.
In summary, our data indicate that B7x plays an important 
role in determining autoimmune susceptibility and in con-
trolling disease severity. In models of diabetes and EAE, we 
found that the molecule plays a role in ameliorating disease by 
inhibiting cytokine production by CD4 T cells. Our data sup-
port the hypothesis that B7x expression in the periphery acts 
as an immune checkpoint to prevent tissue-specific auto-
immunity and thus provides a potential target for therapeutic 
intervention in the clinic.
MATERIALS AND METHODS
Mice. 7–9-wk-old female C57BL/6 mice were purchased from Taconic. 
BDC2.5/B6g7 tg mice were a gift from D. Mathis (Joslin Diabetes Center, 
Boston, MA). To maintain this diabetes-susceptible line, the BDC2.5/B6g7 
transgenics were bred with B6g7 mice, another gift from D. Mathis.
To generate the RipB7x tg mice, B7x was cloned into the Rip7   
cassette, which drives B7x expression under the rat insulin II promoter. The 
mice were bred onto the C57BL/6 background in 12 generations. To use 
these mice for diabetes experiments, the RipB7x line was also bred to homo-
zygosity for the I-Ag7 haplotype by breeding with B6g7 mice. All mice were 
treated in accordance with the National Institutes of Health and American 
Association of Laboratory Animal Care regulations, and experiments were 
approved by University of California, Berkeley and Memorial Sloan-Kettering 
Cancer Center (MSKCC) Institutional Animal Care and Use Committee.
Generation  of  B7x  antibodies. B7x knockout mice were immunized 
with irradiated TrampC2 cells that overexpress B7x mixed with irradiated 
TrampC2 cells that overexpress GM-CSF. 1 d after immunization, the mice 
were given 100 µg –CTLA-4 (clone 9D9; MSKCC Monoclonal Facility). 
4 mo later, the mice received another cellular vaccination followed by two 
boosts of 50 µg B7x Ig (Zang et al., 2003) emulsified in RIBI (Sigma-Aldrich) 
at 1 and 2 mo after second immunization. The spleens were harvested and 
fused to a hybridoma partner by the MSKCC Monoclonal Facility. The re-
sultant antibodies were screened on RMA cells that overexpress B7x. The 
biotinylated antibodies that we used were 19D6, 15D12, 12D11, and 1H3.
Antibodies and flow cytometry. Cells were preincubated with 50 µg/ml 
24.G2 (MSKCC Monoclonal Antibody Core) to block Fc- receptor binding 1692 B7x protects from T cell–mediated autoimmunity | Wei et al.
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splenocytes were then transferred intravenously into sublethally irradiated 
recipients (750 rads).
Cytokine blockade experiments were performed with either 2 mg/
mouse of anti–IFN- (XMG1.2) or control IgG1 (HRPN) or 2 mg/mouse 
of anti–IL-17A (MM17-F3) or control mouse IgG1 (MOPC-21). The anti-
bodies were administered i.p. on days 0, 2, 4, 6, and 8 after transfer.
Histology. Pancreata were fixed with 4% paraformaldehyde and embedded 
in paraffin. The samples were processed and sectioned by the MSKCC Labo-
ratory of Comparative Pathology. Pancreatic sections were stained with H&E 
by the MSKCC Molecular Cytology facility. The slides were analyzed with a 
microscope (AxioPlan 2; Carl Zeiss). Images were collected with a camera 
(Spot; Diagnostic Instruments, Inc.) operated by Spot Advanced software 
(Diagnostic Instruments, Inc.).
For fluorescent microscopy, pancreata were dissected and snap frozen in 
OCT (Tissue-Tek). Sections were fixed with acetone and stained with pri-
mary antibodies overnight at 4°C. After washing, the cells were stained with 
fluorescently conjugated secondary antibodies. The slides were counterstained 
with DAPI and mounted in Slowfade Light Antifade (Invitrogen). The fol-
lowing primary antibodies were used: goat polyclonal anti-B7x (R&D Sys-
tems) and polyclonal guinea pig anti–swine insulin (Dako). The following 
secondary antibodies were used: FITC-conjugated donkey anti–guinea pig 
(Jackson ImmunoResearch Laboratories, Inc.) and Cy5-conjugated donkey 
anti–goat (Jackson ImmunoResearch Laboratories, Inc.). The slides were ana-
lyzed with an inverted microscope (DMIFB/E; Leica). Images were collected 
with a charge-coupled device camera (Quantix; Roper Scientific) operated 
by Slidebook software (Intelligent Imaging Innovations).
EAE induction. Mice were subcutaneously immunized with 10 µg MOG 
emulsified 1:1 in IFA supplemented with 500 µg Mycobacterium tuberculosis 
H37RA (Difco) in the right flank. On days 1 and 3 after immunization, the 
mice received 300 ng pertussis toxin (List Biologicals) intravenously. Clinical 
scores were assessed in a blinded fashion on a scale from 0 to 5 as follows: 0, 
no disease; 0.5, partial limp tail paralysis; 1.0 complete limp tail paralysis 
(flaccid tail); 2, limp tail and hind limb weakness; 3, both hind limb weakness; 
3.5, complete hind limb paralysis; 4, complete hind limb paralysis and 
forelimb weakness; 5, moribund. MOG peptide used was: MOG 35–55, 
MEVGWYRSPFSRVVHLYRNGK.
Isolation  of  CNS-associated  leukocytes  for  intracellular  cytokine 
staining. After anesthetizing with ketamine/xylazine, the mice were per-
fused with PBS, and brains and spinal cords were harvested. Spinal cord tissue 
was flushed out with cRPMI and an 18-gauge needle. The CNS tissue (brain 
and spinal cord) was minced and ground against a 70-µM filter using the 
back of a syringe. After washing with cRPMI, the pellet was resuspended in 
4 ml of 70% Percoll (Sigma-Aldrich) and overlaid with 37% Percoll and 30% 
Percoll. The cell suspensions were then centrifuged for 20 min at 460 g at 
20°C. The leukocytes were harvested at the 37%/70% interface and washed 
again with cRMPI. The cells were then analyzed by flow cytometry.
Statistical analysis. Statistical analysis was performed using Prism software 4 
(GraphPad Software). Data were analyzed by the two-tailed Student’s t test, 
and P < 0.05 was considered statistically significant.
Online supplemental material. Fig. S1 shows that murine DCs do not 
up-regulate  B7x  expression  even  in  various  stimulating,  suppressive,  and 
maturation conditions. Fig. S2 demonstrates that murine macrophages do 
not express B7x even when cultured in different conditions or with Treg cells. 
Fig. S3 shows that blockade of IFN- in a transfer model of diabetes abro-
gates disease incidence, whereas blockade of IL-17A has no effect. Fig. S4 
shows that overexpression of B7x in the pancreata of BDC2.5 mice does not 
expand either a Th2 or Treg cell population. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100639/DC1.
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